Mackenzie Financial Corp Boosts Stock Holdings in Exelixis, Inc. (NASDAQ:EXEL)

Mackenzie Financial Corp raised its holdings in Exelixis, Inc. (NASDAQ:EXEL) by 62.1% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 433,311 shares of the biotechnology company’s stock after purchasing an additional 166,057 shares during the quarter. Mackenzie Financial Corp owned 0.14% of Exelixis worth $9,736,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. LSV Asset Management boosted its stake in shares of Exelixis by 1,651.4% in the first quarter. LSV Asset Management now owns 2,774,707 shares of the biotechnology company’s stock valued at $65,844,000 after buying an additional 2,616,278 shares in the last quarter. Los Angeles Capital Management LLC boosted its position in shares of Exelixis by 948.3% during the 1st quarter. Los Angeles Capital Management LLC now owns 2,454,277 shares of the biotechnology company’s stock worth $58,240,000 after purchasing an additional 2,220,150 shares in the last quarter. Hsbc Holdings PLC grew its stake in shares of Exelixis by 45.3% during the 2nd quarter. Hsbc Holdings PLC now owns 90,211 shares of the biotechnology company’s stock worth $2,031,000 after purchasing an additional 28,126 shares during the period. Farallon Capital Management LLC increased its holdings in shares of Exelixis by 1.6% in the 2nd quarter. Farallon Capital Management LLC now owns 27,102,500 shares of the biotechnology company’s stock valued at $608,993,000 after purchasing an additional 424,000 shares in the last quarter. Finally, True Wealth Design LLC acquired a new stake in shares of Exelixis in the fourth quarter valued at about $828,000. Institutional investors and hedge funds own 85.27% of the company’s stock.

Exelixis Stock Down 0.0 %

EXEL stock opened at $25.95 on Tuesday. The stock has a market capitalization of $7.87 billion, a price-to-earnings ratio of 40.55, a price-to-earnings-growth ratio of 0.56 and a beta of 0.54. Exelixis, Inc. has a 52-week low of $18.64 and a 52-week high of $27.83. The stock’s fifty day simple moving average is $25.63 and its 200-day simple moving average is $23.51.

Exelixis (NASDAQ:EXEL) last issued its quarterly earnings results on Tuesday, August 6th. The biotechnology company reported $0.75 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.31 by $0.44. Exelixis had a return on equity of 15.54% and a net margin of 17.38%. The firm had revenue of $637.18 million for the quarter, compared to analyst estimates of $468.21 million. As a group, analysts anticipate that Exelixis, Inc. will post 1.59 earnings per share for the current fiscal year.

Analyst Ratings Changes

EXEL has been the topic of several recent analyst reports. Oppenheimer restated an “outperform” rating and set a $29.00 target price on shares of Exelixis in a research report on Tuesday, July 30th. JMP Securities reaffirmed a “market outperform” rating and issued a $29.00 price objective on shares of Exelixis in a research note on Friday, September 20th. HC Wainwright reiterated a “buy” rating and set a $29.00 target price on shares of Exelixis in a research report on Wednesday, September 18th. UBS Group began coverage on Exelixis in a research report on Thursday, September 19th. They issued a “neutral” rating and a $30.00 price target for the company. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $27.00 price objective on shares of Exelixis in a research report on Thursday, September 26th. Five analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Exelixis currently has an average rating of “Moderate Buy” and a consensus target price of $27.67.

Insider Activity at Exelixis

In other Exelixis news, EVP Jeffrey Hessekiel sold 25,000 shares of Exelixis stock in a transaction on Monday, September 23rd. The shares were sold at an average price of $26.38, for a total value of $659,500.00. Following the transaction, the executive vice president now owns 605,325 shares in the company, valued at approximately $15,968,473.50. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In related news, EVP Jeffrey Hessekiel sold 25,000 shares of the stock in a transaction on Monday, September 23rd. The stock was sold at an average price of $26.38, for a total value of $659,500.00. Following the transaction, the executive vice president now directly owns 605,325 shares of the company’s stock, valued at approximately $15,968,473.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Maria C. Freire sold 8,250 shares of Exelixis stock in a transaction on Wednesday, August 14th. The shares were sold at an average price of $26.56, for a total value of $219,120.00. Following the completion of the transaction, the director now owns 91,007 shares in the company, valued at approximately $2,417,145.92. The disclosure for this sale can be found here. Over the last three months, insiders sold 327,858 shares of company stock worth $8,640,129. 2.85% of the stock is owned by company insiders.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.